Dr. Lal PathLabs News: Latest Moves in Indian Retail

Latest moves

Our read of each move first, where we have one; what the report said is marked Reported.

Dr Lal PathLabs adds genomics capability and western India reach through SN Genelab, with integration and referral-volume scaling likely to be the near-term operating focus.Reported: Dr Lal PathLabs acquires 70% of SN Genelab for ₹168 crore. The deal strengthens Dr Lal PathLabs’ genomics testing portfolio and expands its presence in western India, though it may be marginally earnings-dilutive initially.28 Sept4 reports from 4 sources, incl. Mint and Financial Express

Background

From 6 stories, the newest dated 28 Sept 2026. Summary written 3 Oct 2026.

Dr. Lal PathLabs is a diagnostics provider in India that operates laboratories and sample collection centres. [1] source: Business Standard

Show 3 more paragraphs and 6 sources

Its Dubai subsidiary is part of the group. [2] source: The Hindu BusinessLine Its West region contributed 14% of FY26 revenue. [3] source: The Hindu BusinessLine

In FY25, Dr. Lal PathLabs added 18 new laboratories and close to 900 sample collection centres, and it plans 15-20 laboratories plus 700-800 centres in the next calendar year. [1] source: Business Standard In September 2026 it agreed to buy a 70% stake in Gujarat-based genomics diagnostics firm SN Genelab for up to ₹168 crore in cash, plus a ₹31.5 crore performance-linked earn-out cap. [4] source: Financial Express [5] source: CNBC-TV18 Mint reported that the deal expands its genomics testing capabilities and western India reach. [6] source: Mint SN Genelab's turnover was ₹57.96 crore in FY26 and ₹53.36 crore in FY25. [5] source: CNBC-TV18 Also in September 2026, Dr Lal PathLabs' Dubai subsidiary completed the acquisition of an 80% stake in Ghana-based Sunshine Healthcare. [2] source: The Hindu BusinessLine

Agilus, Mahajan Imaging and Suraksha are also expanding diagnostics capacity in India. [1] source: Business Standard

Sources

Dr Lal PathLabs to buy 70% of SN Genelab in genomics pushCNBC-TV1824 Sept 2026

How these pages are built Report a correction

Questions about Dr. Lal PathLabs

What is Dr. Lal PathLabs' current strategy in India?

Dr. Lal PathLabs plans 15-20 laboratories plus 700-800 collection centres in the next calendar year. [1] source: Business Standard In September 2026 it agreed to buy 70% of SN Genelab for ₹168 crore, and its Dubai subsidiary completed an 80% stake purchase in Ghana's Sunshine Healthcare. [6] source: Mint [2] source: The Hindu BusinessLine

Stories that mention Dr. Lal PathLabs

3 stories

Dr. Lal PathLabs is named in these stories but is not their subject.